Ruth L Coleman
Overview
Explore the profile of Ruth L Coleman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adler A, Coleman R, Whiteley W, Holman R
Lancet
. 2025 Jan;
405(10472):29.
PMID: 39755389
No abstract available.
2.
Golubic R, Mumbole H, Ismail M, Choo A, Baker O, Atha K, et al.
Diabet Med
. 2024 Dec;
42(3):e15475.
PMID: 39642210
Introduction: In people living with chronic obstructive pulmonary disease (COPD), we aimed to estimate: (1) the prevalence of glucocorticoid-induced hyperglycaemia (GIH); (2) whether the prevalence of GIH varies by age,...
3.
Lin B, Coleman R, Bragg F, Maddaloni E, Holman R, Adler A
Lancet Diabetes Endocrinol
. 2024 Oct;
12(12):904-914.
PMID: 39461360
Background: Younger-onset type 2 diabetes is associated with accelerated complications. We assessed whether complications and mortality rates differed for younger age compared with older age at diagnosis over 30 years...
4.
Oulhaj A, Aziz F, Suliman A, Eller K, Bentoumi R, Buse J, et al.
Diabetes Obes Metab
. 2024 Aug;
26(10):4602-4612.
PMID: 39086032
Aim: The decline in estimated glomerular filtration rate (eGFR), a significant predictor of cardiovascular disease (CVD), occurs heterogeneously in people with diabetes because of various risk factors. We investigated the...
5.
Adler A, Coleman R, Leal J, Whiteley W, Clarke P, Holman R
Lancet
. 2024 May;
404(10448):145-155.
PMID: 38772405
Background: The 20-year UK Prospective Diabetes Study showed major clinical benefits for people with newly diagnosed type 2 diabetes randomly allocated to intensive glycaemic control with sulfonylurea or insulin therapy...
6.
Morrow L, Becker F, Coleman R, Gerstein H, Ryden L, Schoder S, et al.
J Diabetes
. 2023 Nov;
16(2):e13473.
PMID: 37915263
Background: The Acarbose Cardiovascular Evaluation (ACE) trial (ISRCTN91899513) evaluated the alpha-glucosidase inhibitor acarbose, compared with placebo, in 6522 patients with coronary heart disease and impaired glucose tolerance in China and...
7.
Juraschek S, Hu J, Cluett J, Ishak A, Mita C, Lipsitz L, et al.
JAMA
. 2023 Oct;
330(15):1459-1471.
PMID: 37847274
Importance: There are ongoing concerns about the benefits of intensive vs standard blood pressure (BP) treatment among adults with orthostatic hypotension or standing hypotension. Objective: To determine the effect of...
8.
Othonos N, Pofi R, Arvaniti A, White S, Bonaventura I, Nikolaou N, et al.
Nat Commun
. 2023 Feb;
14(1):1025.
PMID: 36823106
Glucocorticoids prescribed to limit inflammation, have significant adverse effects. As 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) regenerates active glucocorticoid, we investigated whether 11β-HSD1 inhibition with AZD4017 could mitigate adverse glucocorticoid effects...
9.
Oulhaj A, Aziz F, Suliman A, Iqbal N, Coleman R, Holman R, et al.
Diabetes Obes Metab
. 2023 Jan;
25(5):1261-1270.
PMID: 36635232
Aim: To demonstrate the gain in predictive performance when cardiovascular disease (CVD) risk prediction tools (RPTs) incorporate repeated rather than only single measurements of risk factors. Materials And Methods: We...
10.
Xu S, Coleman R, Wan Q, Gu Y, Meng G, Song K, et al.
Cardiovasc Diabetol
. 2022 Sep;
21(1):182.
PMID: 36100925
Background: People with intermediate hyperglycemia (IH), including impaired fasting glucose and/or impaired glucose tolerance, are at higher risk of developing type 2 diabetes (T2D) than those with normoglycemia. We aimed...